Patterns of food and acid reflux in patients with low‐grade oesophagitis—the role of an anti‐reflux agent

Washington, N.; Steele, Robert; Jackson, S.J; Washington, C.; Bush, Debbie

doi:10.1046/j.1365-2036.1998.00277.x

Cited by 33 publications

(30 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the inhibition of gastric acid secretion is known to decrease the time that the oesophageal pH < 4, 8,[36][37][38] gastric acidity has received limited attention with respect to its potential underlying role in oesophageal acid exposure in GERD. [39][40][41][42][43][44][45] The present finding that cisapride decreases post-prandial oesophageal acid exposure in subjects with GERD agrees with previous findings by others, [11][12][13][14][15] who have attributed this action of cisapride to its motility effects on the lower oesophageal sphincter pressure, oesophageal peristalsis and gastric emptying. [11][12][13][14][15] Our present results, however, indicate that the decrease in oesophageal acidity can be explained by a cisapride-induced decrease in gastric acidity.…”

Section: Discussionsupporting

confidence: 93%

Cisapride inhibits meal‐stimulated gastric acid secretion and post‐prandial gastric acidity in subjects with gastro‐oesophageal reflux disease

Gardner¹,

Rodriguez–Stanley

Robinson

et al. 2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background and aims : KCNQ1 potassium channels in human gastric parietal cells are thought to be involved in gastric acid secretion. As cisapride can inhibit similar channels in other tissues and is an effective treatment for nocturnal heartburn, we examined the effects of cisapride on gastric and oesophageal acidity, gastric emptying and heartburn severity in subjects with gastro‐oesophageal reflux disease. Methods : Subjects (n=11) had suffered from heartburn four times or more per week for at least 6 months. Gastric pH and oesophageal pH were measured before, during and after a standard meal ingested over 15 min. Each subject received placebo or 10 mg cisapride orally, 30 min before the beginning of the meal. Meal‐stimulated gastric acid secretion was calculated from the amount of HCl required to titrate the homogenized standard meal to pH 2 in vitro and the time required for the pH of the ingested meal to decrease to pH 2 in vivo. Heartburn severity was assessed at 15‐min intervals beginning at the end of the meal. Gastric emptying of solids was measured using a [13C]‐octanoic acid breath test. Results : Cisapride significantly decreased meal‐stimulated gastric acid secretion by 20%, decreased integrated gastric and oesophageal acidity by 50–60% and transiently increased the expiration of 13CO2. Cisapride did not significantly alter heartburn severity. Conclusions : The cisapride‐induced decreases in meal‐stimulated gastric acid secretion, gastric acidity and oesophageal acidity in subjects with gastro‐oesophageal reflux disease can account for its beneficial clinical effects. These results also raise the possibility that gastric KCNQ1 potassium channels are important in meal‐stimulated gastric acid secretion and possibly in the pathophysiology of gastro‐oesophageal reflux disease.

show abstract

Section: Discussionsupporting

confidence: 93%

Cisapride inhibits meal‐stimulated gastric acid secretion and post‐prandial gastric acidity in subjects with gastro‐oesophageal reflux disease

Gardner¹,

Rodriguez–Stanley

Robinson

et al. 2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…In vivo, the alginate raft forms within a few minutes of drug administration and, by floating on top of the gastric contents, preferentially moves into the esophagus during episodes of GOR in place of the acidic gastric contents, thus effectively reducing the likelihood of mucosal damage [9][10][11][12]. Since the raft can be retained on top of the stomach contents for several hours, alginate-based raft-forming formulations can provide longer-lasting relief compared to antacids [7][8][9][10][11][12][13][14]. Therefore, the present study was aimed at comparing sodium alginate and magaldrate, a reference antacid, with respect to symptom relief efficacy, not only in terms of the extent of overall symptom relief but also in terms of the speed and duration of action and safety.…”

Section: Discussionmentioning

confidence: 99%

“…In patients with GORD, it has been shown that alginate-containing preparations reduce the frequency and severity of symptoms [6,7], decrease the number of both food and acid reflux events [8], and limit the proximal migration of refluxed material [7]. Antireflux properties of alginates are based on the interaction with gastric acid to form a strong viscous gel, or alginate raft, which floats on the top of the gastric contents and effectively reduces by physical mechanism the reflux of the gastric contents into the oesophagus [9].…”

mentioning

confidence: 99%

A Comparison Between Sodium Alginate and Magaldrate Anhydrous in the Treatment of Patients with Gastroesophageal Reflux Symptoms

et al. 2006

View full text Add to dashboard Cite

The aims of the present study were to compare effects of sodium alginate and the antacid magaldrate anhydrous in adults with gastroesophageal reflux (GOR) symptoms. Patients with heartburn and/or acid regurgitation for at least 3 days in the week before the study started (n=203) were randomized to receive a single dose of sodium alginate or magaldrate anhydrous at the onset of symptoms during a 3-day run-in period. Patients with symptoms during the run-in (n=191) were rerandomized to receive a 14-day treatment with either drug given as four daily doses. A speed of action < or =30 min was significantly more frequent among patients in the alginate group (49.4% vs. 40.4%; P=0.0074). A trend toward a more prolonged duration of action (median: 16.5 vs. 12.7 hr) and a greater sum of the symptom intensity difference (median: 40.0 vs. 31.0) was observed in the sodium alginate group. Total disappearance of symptoms was reported in 81.6% and 73.9% of patients in the sodium alginate group and magaldrate group, respectively. We conclude that sodium alginate was faster than magaldrate in relieving GRO symptoms and showed a tendency toward a more prolonged duration of action and a higher level of efficacy.

show abstract

“…raising the bed head during sleep) were published during the review period. [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] Impact on recommendations: None. Recommendation: The recommendation is unchanged with respect to the 2004 Consensus (see Table 2) 2.…”

Section: Diet and Lifestyle Changesmentioning

confidence: 99%

Latin American Consensus on Gastroesophageal Reflux Disease: An Update on Therapy

Cohen¹,

Tomasso²,

Cafferata³

et al. 2010

Gastroenterología y Hepatología

View full text Add to dashboard Cite

Patterns of food and acid reflux in patients with low‐grade oesophagitis—the role of an anti‐reflux agent

Abstract: Patients with grades I and II oesophagitis reflux food and acid independently, and are predominantly either food refluxers or acid refluxers, but not both. Liquid alginate decreases the number of both food and acid reflux events, but does not change their duration.

Cited by 33 publications

References 13 publications

Cisapride inhibits meal‐stimulated gastric acid secretion and post‐prandial gastric acidity in subjects with gastro‐oesophageal reflux disease

Cisapride inhibits meal‐stimulated gastric acid secretion and post‐prandial gastric acidity in subjects with gastro‐oesophageal reflux disease

A Comparison Between Sodium Alginate and Magaldrate Anhydrous in the Treatment of Patients with Gastroesophageal Reflux Symptoms

Latin American Consensus on Gastroesophageal Reflux Disease: An Update on Therapy

Contact Info

Product

Resources

About